Compare Essex Property Trust, Inc. (ESS) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs GSK plc — how do they compare? Essex Property Trust, Inc. trades at $272.94 (market cap $17.26B), while GSK plc trades at $46.62 (market cap $91.88B). The key difference: GSK plc is far larger — about 5.3× Essex Property Trust, Inc.'s market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 111 Days and GSK plc for 93 Days on average.
| ESS | GSK | |
|---|---|---|
Market Cap | $17.26B | $91.88B |
Volume | 454,464 | 7,730,529 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $61.18 |
52-Week Low | $239.61 | $43.24 |
Typical Hold Time | 111 Days | 93 Days |
Enterprise Value | $23.86B | $111.88B |
Dividend Yield | 3.86% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $273.21, up 1.93% today, but technical indicators signal a bearish trend with resistance near $273. The company reported mixed quarterly earnings, beating in Q1 but missing in Q2 and Q4 2025, while maintaining strong profitability with a net margin of 21.48%. Recent news highlights strong Q2 2026 results and the resolution of litigation, improving the risk profile.
The outlook is cautiously optimistic with a consensus price target of $303.41, implying upside, but risks include earnings volatility and high debt levels. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid ongoing operational execution challenges in the real estate sector.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
